Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Amortizatization of Intangibles (2018 - 2025)

Historic Amortizatization of Intangibles for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $2.0 million.

  • 10x Genomics' Amortizatization of Intangibles rose 1218.3% to $2.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $7.6 million, marking a year-over-year decrease of 270.79%. This contributed to the annual value of $7.6 million for FY2025, which is 270.79% down from last year.
  • According to the latest figures from Q4 2025, 10x Genomics' Amortizatization of Intangibles is $2.0 million, which was up 1218.3% from $2.0 million recorded in Q3 2025.
  • 10x Genomics' 5-year Amortizatization of Intangibles high stood at $2.3 million for Q1 2024, and its period low was $1.5 million during Q4 2021.
  • Moreover, its 5-year median value for Amortizatization of Intangibles was $1.9 million (2022), whereas its average is $1.9 million.
  • As far as peak fluctuations go, 10x Genomics' Amortizatization of Intangibles soared by 9896.1% in 2021, and later plummeted by 2208.7% in 2025.
  • 10x Genomics' Amortizatization of Intangibles (Quarter) stood at $1.5 million in 2021, then rose by 26.44% to $2.0 million in 2022, then grew by 1.95% to $2.0 million in 2023, then fell by 8.8% to $1.8 million in 2024, then rose by 12.18% to $2.0 million in 2025.
  • Its Amortizatization of Intangibles was $2.0 million in Q4 2025, compared to $2.0 million in Q3 2025 and $1.8 million in Q2 2025.